Should you buy Pharming Group (PHAR)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Below Investable Market Cap→Stable
- Revenue Decline Momentum Weakness→Stable
- High Piotroski Cashflow Quality→Stable
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Below Investable Market Cap
Trip ifMarket cap falls below $0.70 billion, indicating further deterioration in investability and increasing liquidity risk.
- P2Revenue Decline Momentum Weakness
Trip ifRevenue declines more than 15% year-over-year for 2 consecutive quarters, indicating accelerating business contraction.
- P3High Piotroski Cashflow Quality
Trip ifPiotroski F-Score drops below 6 or free cash flow falls below 50% of net income for 2 consecutive quarters.
- P4Analyst Upside Valuation
Trip ifAnalyst consensus price target falls below $18.00, reducing implied upside to less than 40% from current levels.
How the engine reached this verdict
TrendMatrix's engine output for Pharming Group N.V. (PHAR) is SELL_IF_HOLDING with medium conviction, score 4.9/10 at $13.77. The F-path SELL output reflects an overall score of 4.9 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 8.52 is supplementary context, not the trigger.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
On the bull side: Analyst upside: 112%. On the bear side: Earnings expected to decline ~66% (cyclical peak); Weak overall score: 4.9/10; Weak growth. Active engine warnings: V8: Cyclical trap - fwd PE 210x vs trail 72x (2.9x).
The engine's exit framework anchors to a tactical sell band near $13.77, with structural invalidation at $12.93. The asymmetric R:R against a reversal hypothesis is 8.52 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PHAR — 10-dimension breakdown →
Bull case
- ▸Analyst upside: 112%
Bear case
- ▸Earnings expected to decline ~66% (cyclical peak)
- ▸Weak overall score: 4.9/10
- ▸Weak growth